Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes

The US Food and Drug Administration (FDA) needs to reconsider its use of surrogate outcomes in some guidance documents on developing treatments for infectious diseases, researchers from Harvard and George Washington University School of Medicine wrote in a review published Tuesday in JAMA Internal Medicine.